Although plasma cell disorders, such as hypergammaglobulinemia and monoclonal gammopathy of undetermined significance (MGUS) 
Introduction

Multiple myeloma (MM) is characterized by the proliferation of a single clone of plasma cells capable of producing monoclonal immunoglobulins. Interestingly, MM is reported to occur at higher incidences in patients with Type I Gaucher disease (GD) than in the normal population (1, 2). Type I GD is one of the most prevalent lysosomal storage diseases worldwide, and is especially common among Ashkenazi Jews, affecting 1 in~800 individuals (3). It follows an autosomal recessive inheritance and is characterized by a deficiency in glucocerebrosidase (lysosomal enzyme) that leads to excessive accumulation of glucocerebroside (glycolipid substrate) in the macrophages of the reticuloendothelial system (4). Typical manifestations of this multi-system storage disease include hepatosplenomegaly, anemia, thrombocytopenia, skeletal complications, pulmonary involvement, and rarely parkinsonism (4). The relative risk of MM in GD as compared with the general population is estimated to be 5.9% (2)
.
Discussion
Plasma cell disorders such as MM and MGUS may occur in association with GD, where the overall incidence of hematologic malignancies is 6-to 14-fold higher than in the healthy population (1, 2, 6, 7) . The mechanisms for this relationship are poorly understood, but a study of 22 
patients conducted by Allen et al demonstrated significantly elevated interleukin-6 (IL-6) and interleukin-10 (IL-10) concentrations in the serum of patients with GD when compared with those of age-matched controls (8). Both interleukins are important in the regulation of lymphocyte differentiation and their levels are also shown to be increased in lymphoproliferative disorders (9). Specifically, IL-6 has been implicated in the development of osteolytic lesions characteristically seen in MM (8). The presence of high concentrations of IL-6 and IL-10 in both MM and GD suggests that the two conditions may share a common inciting event or pathogenic pathway. The timing of plasma cell disorders in the course of GD is largely unknown. Thus far, all reported cases have described patients with symptomatic GD who subsequently developed immunoglobulin abnormalities (1, 2). The current case contrasts previous reports because our patient was first affected with MM prior to developing clinically apparent GD, indicating that the common temporal pattern of GD
Although clinically asymptomatic from GD when diagnosed with MM, retrospective review of the patient's initial bone marrow biopsy does reveal macrophages resembling Gaucher cells. However, morphologic diagnosis of GD by detecting Gaucher cells in the biopsies of affected organs can be challenging and often requires clinical correlation because Gaucher-like or pseudo-Gaucher cells have been occasionally described to appear in various hematologic malignancies, including lymphomas, leukemias, and MM (10). The paucity of suggestive clinical features and the abundance of plasma cells in the bone marrow at the time clearly indicated that the prominent disease process was MM and therefore our index of suspicion for other diagnoses decreased accordingly.
Persistent unexplained thrombocytopenia, new onset splenomegaly, and possible denovo glomerular disease were evidently the first presenting features of GD in this patient. (11, 12) . Considering the possible role of interleukins in its pathogenesis, a similar reactivation may occur in GD whereby asymptomatic disease can become clinically apparent when a patient's "immune reserve" diminishes following chemotherapy.
They occurred soon after HSCT. Chemotherapy and other forms of immunosuppression may reactivate immunemediated diseases such as tuberculosis and hepatitis
Another noteworthy feature is that the present patient was affected with pure LCMM, which has never been reported to occur in GD. (17, 20, 21 (22, 23) . Such patients demonstrated well-defined glomerulopathy often with Gaucher cells in the glomeruli, but this is not a firm requirement for diagnosis (22, 23 
